J. Braudeau et al. focus on selective negative modulators of GABAA-α5 receptors as a unique cognition enhancing strategy in Down's syndrome (DS), by demonstrating that the selective compound α5IA induces gene expression (c-fos and Arc) and rescues impaired gene expression in the Ts65Dn mouse model of DS. The gene discussed is FOS; the disease is Dravet syndrome.